Cardiovascular Diseases in Survivors of Childhood Cancer

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2020 Feb 7

PMID 32026204

Citations 20

Authors

Neha Bansal

Javier G Blanco

Umesh C Sharma

Saraswati Pokharel

Shannon Shisler

Steven E Lipshultz

Affiliations

Soon will be listed here.

Abstract

Over the past few decades, the diagnosis and management of children with various malignancies have improved tremendously. As a result, there are an increasing number of children who are long-term cancer survivors. With improved survival, however, has come an increased risk of treatment-related cardiovascular complications that can appear decades after treatment. These problems are serious enough that all caregivers of childhood cancer survivors, including oncologists, cardiologists, and other health care personnel, must pay close attention to the short- and long-term effects of chemotherapy and radiotherapy on these children. This review discusses the effects of treatment-related cardiovascular complications from anthracyclines and radiotherapy and the methods for preventing, screening, and treating these complications.

Citing Articles

Late effects of the treatment of childhood cancer.

Roganovic J World J Clin Cases. 2025; 13(7):98000.

PMID: 40051796 PMC: 11612689. DOI: 10.12998/wjcc.v13.i7.98000.

Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats.

Gawrys O, Jichova S, Miklovic M, Huskova Z, Kikerlova S, Sadowski J Hypertens Res. 2024; 47(11):3126-3146.

PMID: 39245782 PMC: 11534684. DOI: 10.1038/s41440-024-01865-7.

Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines.

Liu X, Ge S, Zhang A Children (Basel). 2024; 11(7).

PMID: 39062333 PMC: 11276082. DOI: 10.3390/children11070884.

Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks.

Taghdiri A Egypt Heart J. 2024; 76(1):71.

PMID: 38849680 PMC: 11161443. DOI: 10.1186/s43044-024-00506-1.

Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children.

Meo L, Savarese M, Munno C, Mirabelli P, Ragno P, Leone O Pharmaceutics. 2023; 15(12).

PMID: 38140053 PMC: 10747387. DOI: 10.3390/pharmaceutics15122712.

References

Liu Y, DAmbrosio M, Liao T, Peng H, Rhaleb N, Sharma U . N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2008; 296(2):H404-12. PMC: 2643891. DOI: 10.1152/ajpheart.00747.2008. View

van Dalen E, van den Brug M, Caron H, Kremer L . Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer. 2006; 42(18):3199-205. DOI: 10.1016/j.ejca.2006.08.002. View

Bansal N, Adams M, Ganatra S, Colan S, Aggarwal S, Steiner R . Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2020; 5:18. PMC: 7048046. DOI: 10.1186/s40959-019-0054-5. View

Brown S, Sandhu N, Herrmann J . Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nat Rev Clin Oncol. 2015; 12(12):718-31. DOI: 10.1038/nrclinonc.2015.168. View

Huang Y, Harrison A, Sarkar V, Rassiah-Szegedi P, Zhao H, Szegedi M . Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging. Adv Radiat Oncol. 2017; 1(2):106-114. PMC: 5506699. DOI: 10.1016/j.adro.2016.04.002. View

Rinehart J, Lewis R, Balcerzak S . Adriamycin cardiotoxicity in man. Ann Intern Med. 1974; 81(4):475-8. DOI: 10.7326/0003-4819-81-4-475. View

Jurcut R, Wildiers H, Ganame J, Dhooge J, Paridaens R, Voigt J . Detection and monitoring of cardiotoxicity-what does modern cardiology offer?. Support Care Cancer. 2008; 16(5):437-45. DOI: 10.1007/s00520-007-0397-6. View

Wouters K, Kremer L, Miller T, Herman E, Lipshultz S . Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005; 131(5):561-78. DOI: 10.1111/j.1365-2141.2005.05759.x. View

Lipshultz S, Herman E . Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovasc Res. 2017; 114(2):205-209. PMC: 5852510. DOI: 10.1093/cvr/cvx246. View

10.

Kremer L, van der Pal H, Offringa M, van Dalen E, VOUTE P . Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002; 13(6):819-29. DOI: 10.1093/annonc/mdf167. View

11.

Silber J, Cnaan A, Clark B, Paridon S, Chin A, Rychik J . Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004; 22(5):820-8. DOI: 10.1200/JCO.2004.06.022. View

12.

Fulbright J . Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract. 2011; 2011:942090. PMC: 3102324. DOI: 10.4061/2011/942090. View

13.

Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen P . New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008; 100(15):1058-67. DOI: 10.1093/jnci/djn206. View

14.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

15.

Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L . Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol. 2012; 74(1):180-8. PMC: 3394143. DOI: 10.1111/j.1365-2125.2012.04170.x. View

16.

Tschope C, Van Linthout S . New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2014; 11(4):436-44. PMC: 4221658. DOI: 10.1007/s11897-014-0219-3. View

17.

Herrmann J, Lerman A, Sandhu N, Villarraga H, Mulvagh S, Kohli M . Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014; 89(9):1287-306. PMC: 4258909. DOI: 10.1016/j.mayocp.2014.05.013. View

18.

Antonadou D, Coliarakis N, Synodinou M, Athanassiou H, Kouveli A, Verigos C . Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001; 51(4):915-22. DOI: 10.1016/s0360-3016(01)01713-8. View

19.

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri M . Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7:vii155-66. DOI: 10.1093/annonc/mds293. View

20.

Holler V, Buard V, Gaugler M, Guipaud O, Baudelin C, Sache A . Pravastatin limits radiation-induced vascular dysfunction in the skin. J Invest Dermatol. 2009; 129(5):1280-91. DOI: 10.1038/jid.2008.360. View